Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regenxbio Inc (RGNX)

Regenxbio Inc (RGNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 440,259
  • Shares Outstanding, K 51,613
  • Annual Sales, $ 170,440 K
  • Annual Income, $ -193,880 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 1.14
  • Price/Sales 2.61
  • Price/Cash Flow N/A
  • Price/Book 4.25

Options Overview Details

View History
  • Implied Volatility 205.14% (+11.86%)
  • Historical Volatility 84.39%
  • IV Percentile 75%
  • IV Rank 33.70%
  • IV High 483.38% on 09/23/25
  • IV Low 63.68% on 09/05/25
  • Expected Move (DTE 11) 2.76 (31.39%)
  • Put/Call Vol Ratio 1.12
  • Today's Volume 530
  • Volume Avg (30-Day) 176
  • Put/Call OI Ratio 0.54
  • Today's Open Interest 8,496
  • Open Int (30-Day) 8,582
  • Expected Range 6.04 to 11.56

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-1.36
  • Number of Estimates 6
  • High Estimate $-1.12
  • Low Estimate $-1.61
  • Prior Year $0.12
  • Growth Rate Est. (year over year) -1,233.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.58 +16.09%
on 03/30/26
10.77 -18.29%
on 03/10/26
+0.15 (+1.73%)
since 03/06/26
3-Month
7.58 +16.09%
on 03/30/26
16.19 -45.65%
on 01/22/26
-5.38 (-37.94%)
since 01/06/26
52-Week
5.03 +74.78%
on 04/09/25
16.19 -45.65%
on 01/22/26
+2.51 (+39.90%)
since 04/04/25

Most Recent Stories

More News
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , April 6, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against REGENXBIO Inc. ("Regenxbio"...

RGNX : 8.80 (+3.17%)
REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX

LOS ANGELES , April 6, 2026 /PRNewswire/ --  The DJS Law Group reminds investors of a class action lawsuit against REGENXBIO Inc. ("Regenxbio" or "the Company") (NASDAQ: RGNX ) for violations...

RGNX : 8.80 (+3.17%)
RGNX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In REGENXBIO To Contact Him Directly To Discuss Their Options

RGNX : 8.80 (+3.17%)
RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit

NEW YORK , April 3, 2026 /PRNewswire/ -- 

RGNX : 8.80 (+3.17%)
REGENXBIO, Inc. Class Action Reminder - Robbins LLP Encourages RGNX Stockholders to Contact the Firm for Information About Their Rights

SAN DIEGO , April 3, 2026 /PRNewswire/ -- Robbins LLP  reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired REGENXBIO, Inc. (NASDAQ:...

RGNX : 8.80 (+3.17%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX

NEW YORK , April 2, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against REGENXBIO Inc. ("Regenxbio" or the "Company") (NASDAQ: RGNX). Such investors...

RGNX : 8.80 (+3.17%)
STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: LEVI & KORSINSKY, LLP

Executive Accountability: Stephen Pakola, M.D. Named in REGENXBIO Securities Action

RGNX : 8.80 (+3.17%)
RGNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in REGENXBIO Inc. Securities Lawsuit -- The Gross Law Firm

NEW YORK , March 31, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of REGENXBIO Inc. (NASDAQ: RGNX).

RGNX : 8.80 (+3.17%)
RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit

NEW YORK , March 30, 2026 /PRNewswire/ --

RGNX : 8.80 (+3.17%)
REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX

LOS ANGELES , March 30, 2026 /PRNewswire/ --  The DJS Law Group reminds investors of a class action lawsuit against REGENXBIO Inc. ("Regenxbio" or "the Company") (NASDAQ: RGNX ) for violations...

RGNX : 8.80 (+3.17%)

Business Summary

REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver...

See More

Key Turning Points

3rd Resistance Point 9.35
2nd Resistance Point 9.02
1st Resistance Point 8.77
Last Price 8.80
1st Support Level 8.19
2nd Support Level 7.86
3rd Support Level 7.61

See More

52-Week High 16.19
Fibonacci 61.8% 11.93
Fibonacci 50% 10.61
Fibonacci 38.2% 9.30
Last Price 8.80
52-Week Low 5.03

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.